Literature DB >> 17304042

Obesity and lifestyle management in polycystic ovary syndrome.

Kathleen M Hoeger1.   

Abstract

Polycystic ovary syndrome is frequently associated with obesity, with at least 50% of women with polycystic ovary syndrome demonstrating overweight or obesity defined by body mass index >25 or >30 kg/m. Overweight and obesity impact the clinical reproductive and metabolic features of the syndrome. Long-term complications of obesity such as cardiovascular risk and diabetes, as well as those over the short term in reproductive function, are significantly improved by lifestyle modification. Weight reduction is difficult to achieve over the long-term and programs designed for modest reduction in overall body weight (5% to 10%) with improvements in fitness are as effective as severe weight reduction in reducing metabolic disease and improving ovulatory potential. Further research is needed into the best approach for successful interventions that result in long-term sustained weight loss.

Entities:  

Mesh:

Year:  2007        PMID: 17304042     DOI: 10.1097/GRF.0b013e31802f54c8

Source DB:  PubMed          Journal:  Clin Obstet Gynecol        ISSN: 0009-9201            Impact factor:   2.190


  15 in total

1.  Birthweight, Childhood Body Mass Index, Height and Growth, and Risk of Polycystic Ovary Syndrome.

Authors:  Julie Aarestrup; Dorthe C Pedersen; Peter E Thomas; Dorte Glintborg; Jens-Christian Holm; Lise G Bjerregaard; Jennifer L Baker
Journal:  Obes Facts       Date:  2021-05-12       Impact factor: 3.942

2.  Ovarian hypertension: polycystic ovary syndrome.

Authors:  Rhonda Bentley-Lewis; Ellen Seely; Andrea Dunaif
Journal:  Endocrinol Metab Clin North Am       Date:  2011-06       Impact factor: 4.741

3.  Improvement in quality-of-life questionnaire measures in obese adolescent females with polycystic ovary syndrome treated with lifestyle changes and oral contraceptives, with or without metformin.

Authors:  Miranda Harris-Glocker; Kristin Davidson; Lynda Kochman; David Guzick; Kathleen Hoeger
Journal:  Fertil Steril       Date:  2009-09-24       Impact factor: 7.329

Review 4.  The role of insulin-sensitizing agents in the treatment of polycystic ovary syndrome.

Authors:  Niki Katsiki; Eleni Georgiadou; Apostolos I Hatzitolios
Journal:  Drugs       Date:  2009-07-30       Impact factor: 9.546

Review 5.  Associations Between Serum Magnesium Concentrations and Polycystic Ovary Syndrome Status: a Systematic Review and Meta-analysis.

Authors:  Maedeh Babapour; Hamed Mohammadi; Maryam Kazemi; Amir Hadi; Mahsa Rezazadegan; Gholamreza Askari
Journal:  Biol Trace Elem Res       Date:  2020-08-18       Impact factor: 3.738

6.  Predictors of pregnancy after intrauterine insemination in women with polycystic ovary syndrome.

Authors:  Hui-Juan Guan; Lin-Qing Pan; Hang Song; Huai-Yun Tang; Li-Sha Tang
Journal:  J Int Med Res       Date:  2021-05       Impact factor: 1.671

7.  State of the Art Review: Emerging Therapies: The Use of Insulin Sensitizers in the Treatment of Adolescents with Polycystic Ovary Syndrome (PCOS).

Authors:  David H Geller; Danièle Pacaud; Catherine M Gordon; Madhusmita Misra
Journal:  Int J Pediatr Endocrinol       Date:  2011-08-26

8.  The characterization of obese polycystic ovary syndrome rat model suitable for exercise intervention.

Authors:  Chuyan Wu; Feng Lin; Shuwei Qiu; Zhongli Jiang
Journal:  PLoS One       Date:  2014-06-06       Impact factor: 3.240

9.  Effects of aerobic exercise on plasma lipoproteins in overweight and obese women with polycystic ovary syndrome.

Authors:  Elaheh Abazar; Farzaneh Taghian; Farahnaz Mardanian; Dashti Forozandeh
Journal:  Adv Biomed Res       Date:  2015-03-25

10.  Reduction in corpora lutea number in obese melanocortin-4-receptor-deficient mice.

Authors:  Mara Sandrock; Angela Schulz; Claudia Merkwitz; Torsten Schöneberg; Katharina Spanel-Borowski; Albert Ricken
Journal:  Reprod Biol Endocrinol       Date:  2009-03-24       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.